Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC
Accepted 2024-12-23 00:00:00 ET · period of report 2024-12-19 · accession 0001127602-24-029965 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-23 | 2024-12-19 | BCRX | Doyle Anthony | CFO | A - Grant | $0.00 | +120.7K | 380.3K | +46% | $0 |
| D | 2024-12-23 | 2024-12-19 | BCRX | Doyle Anthony | CFO | F - Tax | $7.39 | -2,461 | 377.9K | -0.6% | -$18.2K |
| D | 2024-12-23 | 2024-12-19 | BCRX | Doyle Anthony | CFO | A - Grant | $0.00 | +250.1K | 250.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-19 | A | A | 120,700 | $0.00 | 380,328 | D | — | — | (F1) Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. |
| 2 | Common | Common Stock | 2024-12-19 | F | D | 2,461 | $7.39 | 377,867 | D | — | — | (F2) Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person. |
| 3 | Derivative | Emp. Stock Option (Right to Buy) | 2024-12-19 | A | A | 250,100 | $0.00 | 250,100 | D | $7.39 · 2025-12-19 to 2034-12-19 | 250,100 Common Stock | (F3) Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. |